The 24 months since commercial production of the medical isotope began at the Candu unit have seen Bruce Power and its partners expand production capabilities to match growing global demand.
A 50% increase in molybdenum-99 and 22% more iodine-131 will be produced by adding an extra shift and increasing the hours of irradiation at the RA-3 reactor, Argentina's National Atomic Energy Commission (CNEA) has said.
Romania's nuclear power plant operator Nuclearelectrica and France's Framatome are aiming to launch a full-scale commercial irradiation service for medical isotopes in 2028.
TerraPower Isotopes announced it is producing actinium-225 at commercial scale. The medical radioisotope is being produced from material recovered from a legacy uranium-233 inventory at a US national laboratory.